Vivanza Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	3.94	-6.74	5.47	5.98	3.33
Depreciation & Amortization	0.22	0.14	0.12	0.03	0.07
Other Operating Activities	2.8	3.53	4.12	4.19	4.05
Change in Accounts Receivable	-43.24	34.8	9.4	-46.39	-15.9
Change in Inventory	-12.88	-2.57	4.68	-0.47	-17.75
Change in Accounts Payable	45.76	-56.17	-13.15	40.64	16.2
Change in Other Net Operating Assets	-22.4	2.02	9.79	-13.44	34.66
Operating Cash Flow	-25.79	-24.99	20.44	-9.46	24.67
Capital Expenditures	-1.24	-0.08	-0.38	-	-
Investing Cash Flow	-1.24	-0.08	-0.38	-	-
Long-Term Debt Issued	39.97	28.3	-	36.53	-
Total Debt Issued	39.97	28.3	-	36.53	-
Long-Term Debt Repaid	-	-	-40.77	-	-6.04
Total Debt Repaid	-	-	-40.77	-	-6.04
Net Debt Issued (Repaid)	39.97	28.3	-40.77	36.53	-6.04
Other Financing Activities	-13.46	-3.73	20.96	-26.21	-18.73
Financing Cash Flow	26.52	24.57	-19.8	10.32	-24.77
Miscellaneous Cash Flow Adjustments	-	-0	-	-	-
Net Cash Flow	-0.52	-0.5	0.26	0.86	-0.1
Free Cash Flow	-27.03	-25.07	20.06	-9.46	24.67
Free Cash Flow Margin	-2.33%	-33.55%	7.19%	-5.21%	22.03%
Free Cash Flow Per Share	-0.69	-0.63	0.51	-0.24	0.62
Cash Interest Paid	2.79	3.51	4.13	4.19	4.06
Cash Income Tax Paid	1.49	0.07	1.49	1.18	0.01
Levered Free Cash Flow	-28.15	-29.53	35.53	-27.11	-23.72
Unlevered Free Cash Flow	-26.4	-27.34	38.11	-24.49	-21.19
Change in Working Capital	-32.75	-21.92	10.73	-19.65	17.22

Source: S&P Global Market Intelligence. Standard template. Financial Sources.